Veza Unveils New NHI Security Product to Tackle the Fastest-Growing Risk in Identity Security in the AI Era
REDWOOD SHORES, Calif.--(BUSINESS WIRE)-- Veza, the identity security company, today announced a significant platform expansion focused on securing Non-Human Identities (NHIs). The new NHI Security product and capabilities deliver visibility, ownership, and governance to machine identities—such as service accounts, secrets, keys, and workloads—across SaaS, cloud, infrastructure, and on-premises environments.
As enterprises rush to adopt AI, they're unleashing a flood of machine identities faster than anyone can control. Every model, training run, and inference call spins up new credentials that access sensitive data and systems. These AI workloads don't just add scale, they introduce chaos. Machine identities now outnumber humans 17 to 1, and most are invisible, ownerless, and dangerously overprivileged. They're powering core business processes, yet flying completely under the radar. Worse, threat actors like Volt Typhoon are deliberately targeting identity as their primary attack surface.
Veza brings order to this chaos by giving organizations a structured, automated way to discover, govern, and lock down NHIs—with the same rigor applied to humans. From visibility to ownership to least privilege, Veza puts security back in control of the machines that now run your business. Veza's NHI adoption is surging because enterprises aren't waiting to become the next headline. The risk is real, the sprawl is unchecked, and the only way forward is to act now.
'Non-human identities in our Azure estate—service principals, managed identities, and the secrets that support our custom applications—have been a blind spot," said Lena Taylor, VP, Chief Information Security Officer at Crocs. "As we roll out Veza, we will have a single, centralized view to discover, monitor, and govern these machine identities. The ability to assign clear ownership, surface risk, and enforce least-privilege across Azure is already reshaping how we approach identity security, and we're excited to see the full impact as deployment continues.'
Now available in the Veza Access platform, Veza NHI Security product provides a purpose-built product offering for machine identities—backed by deep analytics, full lifecycle insights, and automation integrated with Veza's platform. Highlights include:
Comprehensive NHI Discovery and Visibility: Easily access the new NHI Security module in Veza to view a unified inventory of NHIs, including AWS EC2 instances, Azure VMs, GCP clusters, Entra ID service principals, Okta, Salesforce, HashiCorp, and many more. Veza automatically classifies NHIs using advanced logic and lets you refine via enrichment rules to fit your environment.
Automated Risk Detection and Mitigation: Pre-built access risk dashboards highlight critical risks such as dormant keys, unrotated secrets, orphaned accounts, and NHIs with excessive permissions. Drill down into key and secret metadata—like last used, rotation status, and active state—across systems like AWS KMS, Azure Key Vault, HashiCorp Vault, GitHub, and Salesforce.
Human to Non-Human Ownership Management: Get real-time alerts when an NHI becomes orphaned or its human owner leaves the org. Veza suggests a new owner based on access intelligence and allows you to reassign with a single click. Use Veza Enrichment Rules for advanced use cases (e.g. workload identity, ephemeral instances, non-human to non-human, etc.).
Integrated Compliance Control: Maintain compliance with automated tracking of NHI ownership, credential hygiene, and least privilege enforcement—backed by Access Graph visualizations and risk scoring for every non-human identity.
With Veza's new NHI capabilities, customers:
Improve Security: Eliminate dormant accounts, detect unknown access paths, and reduce the blast radius of potential breaches.
Reduce Risk and Compliance Gaps: Prove key rotation and least privilege enforcement for machines and workloads.
Eliminate Access Uncertainty: Understand the true scale of your NHI footprint—even when machine identities masquerade as human users.
'NHI discovery and lifecycle are mission-critical use cases for enterprises operating in the real world of cloud, identity complexity, and Agentic AI adoption,' said Tarun Thakur, CEO and Co-Founder of Veza. 'NHI Security isn't actually an identity in your directory services, the machine identities are everywhere across SaaS, databases, cloud, disconnected systems, and now AI apps. Veza is delivering the next-gen identity platform designed on the permissions and entitlements metadata to help organizations achieve least privilege at scale as the foundation to Zero Trust.'
About Veza
Veza is the leader in identity security, helping organizations secure access across the enterprise. Veza's Access Platform goes beyond identity governance and administration (IGA) tools to visualize, monitor, and control entitlements so that organizations can stay compliant and achieve least privilege. Global enterprises like Wynn Resorts, Expedia, and Blackstone trust Veza to manage identity security use cases, including privileged access monitoring, non-human identity (NHI) security, access entitlement management, data system access, SaaS access security, IAM hygiene, identity security posture management (ISPM), and next-generation IGA. Founded in 2020, Veza is headquartered in Los Gatos, California, and is funded by Accel, Bain Capital, Ballistic Ventures, Google Ventures (GV), NEA, Norwest Venture Partners, and True Ventures. Visit us at www.veza.com and follow us on LinkedIn, X, and YouTube.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 hours ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
9 hours ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
10 hours ago
- Business Wire
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions
MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit
